Tagged with Mexico

Mexico Ana Riquelme Francistain, executive director of the MedTech trade group Asociación Mexicana de Industrias Innovadoras de Dispositivos Médicos (AMID), details the trade and tax incentives that have favoured nearshoring from the US. Additionally, she outlines the sector’s regulatory advances, the important regulatory updates with respect to labelling, good manufacturing practices…

Mexico Four years ago, Daniel Del Conde left a career in multinational pharma to become the CEO of regional player Grupo Somar. He walks us through the company’s activities – private labels; pure generics; private brand manufacturing, and prescription, its recent acquisition of Quifa, and the diversified portfolio that encompasses over…

Mexico While the COVID-19 pandemic revealed vulnerabilities that sent many organizations looking for ways to bring supply chains closer to home, geopolitical tensions have also encouraged companies to avoid dependence on China. MedTech, like the automotive sector, is turning to Mexico where it can easily reach the vast North American market…

Mexico In a move to address medicine shortages Mexico’s outgoing president Andrés Manuel López Obrador last year launched a Super Pharmacy, or “Megafarmacia del Bienestar,” dubbed the largest medicine stockpile n the world. But with the country’s presidential elections looming and evidence that few prescriptions have actually been filled, detractors say…

Mexico The latest stories from Mexican pharma and healthcare, including Sanfer’s purchase of Colombia-based manufacturer Vitalis; Organon Mexico’s new business; the FDA’s warning to Glicerinas Industriales, and a look at the issues, including health, the new Mexican president will have to face.   Mexico’s Health Ministry issues measles alert (Mexico News) Mexico’s…

LatAm An overview of some of the biggest stories from Latin American pharma and healthcare, including Brazil’s rollout of dengue vaccines following a sharp increase in cases; the Brazilian  regulatory agency ANVISA’s strategy to become a WHO-listed authority andAspid Pharma’s agreement with Institute for Research on Obesity of the Tecnológico de…

LatAm A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards universal primary health coverage with support from the World Bank.   ACON Investments Signs Definitive Agreement to Sell Vitalis to…

Mexico Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will also mark another historic first as the two leading presidential hopefuls are women: Claudia Sheinbaum of the incumbent president Andres…

LatAm A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s decision to issue a compulsory license for GSK/ViiV’s HIV treatment.   Colombia set to issue a compulsory license for an…

Mexico The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.   Dow and Azelis México, distribution partners for the pharmaceutical market (T21, in Spanish) Dow announced its alliance with Azelis,…

LatAm Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the region and delivered consistent growth in most of its LatAm markets. He also explains how the region is confronting some…

Americas Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth and plans to launch 14 new products there by 2025, most importantly its European Medicines Agency-approved dengue vaccine. She also…